With nothing more than a quick glance, March's jobs report was a bit alarming. We only added 103,000 new positions, and the unemployment rate actually didn't edge lower to 4.0%, as was expected. That's a far cry from the 326,000 new payrolls added in February, particularly in light of the fact that we're allegedly in the midst of a booming...
– Considering the potential bottom in three types of market decline – By Ryan Vlastelica, MarketWatch The U.S. stock market has seen extreme volatility over the past two months, as investors grapple with the prospect of a trade war, potential regulation for large-capitalization internet companies, and changing monetary policy from the Federal Reserve. No doubt, many investors are wondering how...
– Considering the potential bottom in three types of market decline – By Ryan Vlastelica, MarketWatch The U.S. stock market has seen extreme volatility over the past two months, as investors grapple with the prospect of a trade war, potential regulation for large-capitalization internet companies, and changing monetary policy from the Federal Reserve. No doubt, many investors are wondering how...
On Thursday, some not-entirely-surprising news surfaced. Hedge fund manager, once a star among the gain-seeking, risk-averse crowd, is on the defensive in a big way. His fund, Pershing Square, is seeing more and more cash-outs, as investors disappointed in his results simply want to take what's left of their money and do something else with it. The specifics: Once a...
On Thursday, some not-entirely-surprising news surfaced. Hedge fund manager, once a star among the gain-seeking, risk-averse crowd, is on the defensive in a big way. His fund, Pershing Square, is seeing more and more cash-outs, as investors disappointed in his results simply want to take what's left of their money and do something else with it. The specifics: Once a...
The 'morphine drip' preventing stock pain is ending, analyst says By Ryan Vlastelica, MarketWatch Over the past several weeks, policy uncertainty has been the biggest driver of moves in the U.S. stock market, with investors fretting that protectionist measures pushed by President Donald Trump could escalate into a trade war, or that recent issues surrounding internet companies could herald a...
The 'morphine drip' preventing stock pain is ending, analyst says By Ryan Vlastelica, MarketWatch Over the past several weeks, policy uncertainty has been the biggest driver of moves in the U.S. stock market, with investors fretting that protectionist measures pushed by President Donald Trump could escalate into a trade war, or that recent issues surrounding internet companies could herald a...
By Keris Lahiff, CNBC Amid sharp sell-offs and quick rebounds, one strategist forecasts a possible bear market for Wall Street before all is said and done. "I wouldn't be surprised if we saw a 15 percent or even a 20 percent move off the highs before this thing finally bottoms out," Matt Maley, equity strategist at Miller Tabak, told CNBC's...
By Keris Lahiff, CNBC Amid sharp sell-offs and quick rebounds, one strategist forecasts a possible bear market for Wall Street before all is said and done. "I wouldn't be surprised if we saw a 15 percent or even a 20 percent move off the highs before this thing finally bottoms out," Matt Maley, equity strategist at Miller Tabak, told CNBC's...
As far as rebound efforts go, Tuesday's bullishness wasn't exactly what the optimists wanted to see. The gain didn't undo all of Monday's damage, and the advance the market was able to muster was a low-volume effort. Generally speaking, for a move to have any follow-through, it needs more – not less – participants. In retrospect, one can't help but...
BECOME A BIG TRENDS INSIDER NOW!
Trend Watch, TRENDSCORE, webinars, technical analysis e-book, and more!
